Related Experiment Videos
The dawn of genetic testing for glaucoma
Claudia S Cohen1, R Rand Allingham
1Duke University, Durham, North Carolina, USA.
Current Opinion in Ophthalmology
|March 17, 2004
Summary
Genetic testing for glaucoma is emerging, with a new test for a primary open angle glaucoma (POAG) risk factor showing controversial results. Further research is needed to clarify the role of the MYOC.mt1 variant in POAG.
Area of Science:
- Ophthalmology
- Genetics
- Molecular Biology
Background:
- Genetic testing is increasingly used in medicine.
- Primary open angle glaucoma (POAG) is a common form of glaucoma.
- The myocilin gene (MYOC) is implicated in POAG pathogenesis.
Purpose of the Study:
- To review recent trends in genetic testing for glaucoma.
- To evaluate the utility of newly evolving genetic tests for glaucoma patients.
- To discuss the implications of genetic testing in glaucoma management.
Main Methods:
- Review of recent literature on genetic testing in glaucoma.
- Analysis of studies investigating the MYOC.mt1 variant in POAG.
- Discussion of the clinical and societal issues surrounding genetic testing.
Main Results:
- A commercially available test for the MYOC.mt1 variant in the myocilin gene is now available.
- Studies show conflicting results regarding the association between MYOC.mt1 and POAG severity.
- The role of MYOC.mt1 in the pathogenesis of POAG requires further investigation.
Conclusions:
- Genetic testing for glaucoma shows significant promise for personalized medicine.
- Current genetic tests for glaucoma risk factors, such as MYOC.mt1, yield controversial results.
- Further research is essential to validate the clinical utility of genetic testing in glaucoma care.